Astx727

Chronic Myelomonocytic Leukemia

Taiho Oncology, Inc.Phase 3Active

BB

66/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 62/ 100
Competitive Position: 73/ 100

Competitive context

97 Active assets in the Chronic Myelomonocytic Leukemia cohort.

Asset / Sponsor	Phase	Rating
Pevonedistat Takeda	Phase 3	BB
Venetoclax Servier Bio-Innovation LLC	Phase 2/3	BB
Azacitidine The University of Hong Kong	Phase 3	BB
CYCLOSPORIN A Fred Hutchinson Cancer Center	Phase 2	BB
Idarubicine Fred Hutchinson Cancer Center	Phase 3	BB

View all 50 →

Same molecule, other indications

Astx727 is also rated in:

myelodysplastic syndromeDormant

BB

Indicative ·

66 / 100

acute myeloid leukemiaDormant

BB

Indicative ·

64 / 100

colorectal cancerDormant

CCC

Indicative ·

50 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.